Synaptogenix | Neurotrope Holds Investigators Meeting for U.S. Phase 2b Trial of Bryostatin-1 for Treatment of Alzheimer’s Disease
post-template-default,single,single-post,postid-22478,single-format-standard,ajax_fade,page_not_loaded,,select-theme-ver-4.4,wpb-js-composer js-comp-ver-5.4.7,vc_responsive

Neurotrope Holds Investigators Meeting for U.S. Phase 2b Trial of Bryostatin-1 for Treatment of Alzheimer’s Disease


More than 150 Attendees from 30 Sites Nationwide


Newark, NJ, February 3, 2016 – Neurotrope, Inc. (NTRP) today announced that it has held an Investigators Meeting in conjunction with its recently initiated Phase 2b trial for lead compound, Bryostatin-1 for the treatment of Alzheimer’s disease. The meeting, held January 28-29, 2016 in Orlando, Florida, brought together more than 150 healthcare clinical professionals from 30 sites across the United States to discuss the goals for the study, in addition to providing the in-depth training necessary for the trial.


“There was substantial excitement at the prospect of advancing the development of our novel drug as a treatment for severe Alzheimer’s disease,” said Charles S. Ramat, President and Chief Executive Officer of Neurotrope. “The meeting gave us an opportunity to hear firsthand from doctors about their frustrations at watching helplessly as patients decline with no therapy to alleviate their symptoms. The doctors’ excitement at the potential of Bryostatin to reverse this trend was overwhelming and emotional.”


The Bryostatin-1 Phase 2b trial is an ongoing randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability and efficacy of the drug in the treatment of patients suffering from moderately severe to severe Alzheimer’s disease. The study plans to enroll 150 patients at a total of 30 participating U.S. sites.


About Neurotrope


Neurotrope BioScience, Inc., a wholly owned subsidiary of Neurotrope, Inc., is at the forefront of biotechnology companies having a focus on developing a novel therapy for the treatment of moderately severe to severe Alzheimer’s disease. The scientific basis of our treatment is activation of Protein Kinase C isozymes ε and α by bryostatin, a natural product, which can result in repair of damaged synapses as well as synaptogenesis, reduction of toxic amyloid generation, and enhancement of memory and learning, thus having the potential to improve cognition and behavior in Alzheimer’s disease.  


Neurotrope is also conducting preclinical studies of bryostatin as a treatment for Fragile X Syndrome and Niemann-Pick Type C disease, two rare genetic diseases for which only symptomatic treatments are currently available. The Food and Drug Administration has granted Orphan Drug Designation to Neurotrope for bryostatin as a treatment for Fragile X Syndrome.


NTRP has exclusively licensed technology from the Blanchette Rockefeller Neurosciences Institute for Alzheimer’s disease and Fragile X Syndrome, has a world-wide, exclusive license with the Icahn School of Medicine at Mt. Sinai for Niemann-Pick Type C disease and is partnered with Stanford University to synthesize and find the next generation bryostatin – called bryologs.


Forward-Looking Statements


Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. These forward-looking statements include statements regarding the proposed study and timing of initiation, and continued development of use of bryostatin for Alzheimer’s disease and other cognitive diseases, and the Company’s ability to list its common shares on a major stock exchange.  Such forward-looking statements are subject to risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or cause actual results to differ materially from expected or desired results may include, without limitation, the Company’s inability to obtain adequate financing, the significant length of time associated with drug development and related insufficient cash flows and resulting illiquidity, the Company’s patent portfolio, the Company’s inability to expand the Company’s business, the Company’s inability to meet listing requirements for major stock exchanges, significant government regulation of pharmaceuticals and the healthcare industry, lack of product diversification, availability of the Company’s raw materials, existing or increased competition,  stock volatility and illiquidity, and the Company’s failure to implement the Company’s business plans or strategies. These and other factors are identified and described in more detail in the Company’s filings with the SEC, including the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2015. The Company does not undertake to update these forward-looking statements.


Please visit for further information.



For additional information, please contact:

The Ruth Group for Neurotrope Bioscience:

Lee Roth (Investors) / Kirsten Thomas (Media)

646-536-7012 / 508-280-6592 /